bosentan anhydrous has been researched along with 2019 Novel Coronavirus Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Javor, S; Salsano, A | 1 |
| Cabrales, P; Knox, S; Oronsky, A; Oronsky, B; Reid, TR | 1 |
2 other study(ies) available for bosentan anhydrous and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Why not consider an endothelin receptor antagonist against SARS-CoV-2?
Topics: Anti-Inflammatory Agents; Antiviral Agents; Betacoronavirus; Bosentan; Cells, Cultured; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokines; Drug Evaluation, Preclinical; Drug Therapy, Combination; Endothelin A Receptor Antagonists; Humans; Models, Biological; Pandemics; Pneumonia, Viral; Receptor, Endothelin A; RNA, Viral; SARS-CoV-2; Valsartan; Virus Diseases | 2020 |
Desperate Times, Desperate Measures: The Case for RRx-001 in the Treatment of COVID-19.
Topics: Antihypertensive Agents; Azetidines; Bosentan; COVID-19; COVID-19 Drug Treatment; Drug Repositioning; Humans; Lung; Nitric Oxide Donors; Nitro Compounds; Pandemics; SARS-CoV-2 | 2020 |